Abstract
Paclitaxel and docetaxel, drugs that bind tightly to β-tubulin and disrupt microtubule dynamics, are widely used in the treatment of non-small cell lung cancer (NSCLC), the most common cause of cancer death in men and women living in the US. These well tolerated drugs, alone or in combination with another cytotoxic agent, have been shown to increase the survival of patients with metastatic disease or malignant effusions. Both paclitaxel and docetaxel can be combined with concurrent chest irradiation for patients with locally advanced NSCLC. The combination of carboplatin and paclitaxel, when given postoperatively to patients with stage IB NSCLC, improved survival compared with surgery alone, with little toxicity. Taxane combinations are undergoing study as adjuvant therapy for patients with other stages of operable disease. Except for a recent trial with bevacizumab, efforts to improve the efficacy of taxane/platinum combinations in patients with advanced disease by adding a third ‘targeted’ drug have thus far been unsuccessful.
Similar content being viewed by others
Notes
1 The use of trade names is for product identification purposes only and does not imply endorsement.
References
Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26
Bailey-Wilson JE, Arnos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23–25. Am J Hum Genet 2004; 75: 460–74
Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–42
Page N, Read W, Tierney M, et al. The epidemiology of small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 210
Minna JD, Fong K, Zochbauer-Muller S, et al. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 2002; 8 Suppl. 1: 41-6
Danesi R, De Braud F, Fogli S, et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55: 57–103
Thomas J, Lynch DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129–39
Rowinsky EK, Onetto N, Canetta RM, et al. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19(6): 646–62
Giannakakou P, Nakano M, Nicolaou K, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002; 99: 10855–60
Leonard G, Fojo T, Bates S. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411–24
Rosell R, Taron M, Alberola V, et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003; 41 Suppl. 1: S97-102
Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22(23): 3548–53
Giannakakou P, Sackett D, Kang Y, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118–25
Kelley M, Li S, Harpole D. Genetic analysis of the beta-tubulin gene, TUBB, in non-small cell lung cancer. J Natl Cancer Inst 2001; 93: 1886–8
Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004; 5(3): 158–64
Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22(19): 3852–9
Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21
Stephens RJ, Fairlamb D, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21: 1161a
Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 1074–80
Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27(3): 145–57
Lilenbaum RC, Herndon 2nd JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B. J Clin Oncol 2005; 23: 190–6
Georgoulias V, Ardavanis A, Agelidou M, et al. Preliminary analysis of multicenter phase III trial comparing docetaxel versus docetaxel/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: 291a
Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. JAMA 2004; 292(4): 470–84
Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3): 623–31
Kelly K. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210–8
C. Belani CP, Larocca RV, Renaldi DA, et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc Am Soc Clin Oncol 2004; 22: 621s
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8
Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21(16): 3016–24
Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21(21): 3909–17
Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13(10): 1539–49
Dillman R, Seagren S, Propert K, et al. A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940–5
Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable Stage III nonsmall cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the ECOG. J Clin Oncol 1999; 17: 4–11
Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 417–23
Schaake-Konig C, Van dan Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524–30
Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group and southwest oncology group. Chest 2000; 117: 358–64
Soresi E, Clerici M, Grilli R, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiamine platinum in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1998; 15: 20–5
Jeremec B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996; 14: 1065–70
Marino P, Preatoni A, Cantoni A, et al. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB nonsmall cell lung cancer: a met-analysis. Cancer 1995; 76: 593–601
Dillman R, Herndon J, Seagren S, et al. Improved survival in stage III non-small cell lung cancer: seven-year followup of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–5
Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9): 2692–9
Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2003; 22: 621a
Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 312a
Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20: 4191–8
Kiura K, Ueoka H, Segawa Y, et al. Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003; 89(5): 795–802
Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 2005; 23: 5883–91
Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21(10): 2004–10
Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small-cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23: 618s
Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000; 343: 1217–22
Scagliotti GV, Fossati R, Torri V, et al. Randomized trial of adjuvant chemotherapy for completely resected stage I, II or IIIA non small lung cancer. J Natl Cancer Inst 2003; 95: 1453–61
Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–60
Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med 2005; 352: 2589–97
Strauss GM, Hernton J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 23: 621s
Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153–8
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80
Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a seven year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7–14
Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998; 21: 1–6
Albain KS, Scott CB, Rusch VR, et al. phase III comparison of concurrent chemotherapy plus radiotherapy (ct/rt) and ct/rt followed by surgical resection for stage iiia (pn2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22: 386
Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000; 119: 429–39
Spira A, Ettinger D. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379–2
Hainsworth JD, Thompson DS, Greco FA, et al. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609–14
Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38 Suppl. 4: 5-12
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095–103
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18(12): 2354–62
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589–97
Williamson SK, Crowley JJ, Lara PN, et al. S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). a phase 3 Southwest Oncology Group (SWOG) trial [abstract no. 2502]. Proc Am Soc Clin Oncol 2003 May 31, 622
Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41 Suppl. 1: S9–S15
Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotnib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123–32
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2. J Clin Oncol 2004; 22(5): 785–94
Herbst RS, Prager D, Hermann R, et al. Tribute: a phase III trial of erlotinib combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 5892–9
Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46(5): 387–93
Khuri FR, Glisson BS, Kim ES, et al. Phase 1 Study of the farnesyl transferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004 May 1; 10(9): 2968–76
Blumenschein Jr G, Ludwig C, Thomas G, et al. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer [abstract]. 11th World Congress on Lung Cancer, International Association for Study of Lung Cancer; 2005 July 3–6; Barcelona, Spain [online]. Proceedings available at URL: http://www.IASLC.org [Accessed 2006 Apr 14]
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel along in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91
Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer [abstract]. J Clin Oncol 2005; 23 Suppl. 16: LBA4
Fannucchi MP, Fossella F, Fidias P, et al. Bortezomib +/- docetaxel in previously treated patients with advanced non-small cell lung cancer: a phase 2 study [abstract]. J Clin Oncol 2005; 23 Suppl. 16: 7034
Lynch T, Raju R, Lind M, et al. Randomized phase III trial of chemotherapy and antisense nucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 2003; 22: 22
Laskin J, Sandier A. The importance of the eicosanoid pathway in lung cancer. Lung Cancer 2003; 41 Suppl. 1: S73–81
Wolff A, Donehower R, Carducci M, et al. Phase I study of Docosahexanoic Acid-Paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2004; 9: 3589–97
Kosmidis P, Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer 2003; 41 Suppl. 1: S123–33
Acknowledgments
The authors receive financial support from the Emory University Winship Cancer Institute.
Dr Fanucchi has received research support from Bristol Meyers Squibb, Sanofi-Aventis, Novartis, Schering Plough, Millennium Pharmaceuticals. Dr Khuri has received research support from Sanofi-Aventis, Novartis, Schering Plough, Ligand Pharmaceuticals.
Additionally, Dr Khuri receives funding from the Department of Defense (DAMD 17-01-1-0689 Hong [PI], DAMD 17-02-1-0706 [Hong], DAMD W81XWH-04-1-0142 [Hong]), NIH/NCI (U01-CA21661-24, P50 CA97007-01 [Hong], P50 CA70907, DAMD [Hong], Eastern Cooperative Oncology Group Core Grant, NCI (1P20 CA103735-01), and the Georgia Cancer Coalition.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fanucchi, M., Khuri, F.R. Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treat Respir Med 5, 181–191 (2006). https://doi.org/10.2165/00151829-200605030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151829-200605030-00004